Korea Health Industry Development Institute Hosts 'Bio Korea 2022' Conference

[Asia Economy Reporter Lee Chun-hee] The Korea Health Industry Development Institute announced on the 27th that it will hold the 'BIO KOREA 2022' conference, where the current status of the global biohealth industry can be understood, at COEX in Seoul from the 11th to the 13th of next month.

Now in its 17th year, BIO KOREA 2022 consists of a conference, business forum, exhibition, and invest fair. It is a business event that brings together executives in the biohealth field from around the world, consulting experts, related researchers, policy makers, and investors in one place.

This year's BIO KOREA is held under the theme "Beyond the Pandemic, into A Next Wave." It shares changes in the biohealth industry and technology development trends in the 'new normal' situation after COVID-19. Research teams and researchers actively participating include those from national R&D projects such as the National New Drug Development Project Group, Vaccine Commercialization Technology Development Project Group, Dementia Overcoming Research and Development Project Group, Pan-Government Regenerative Medicine Technology Development Project Group, and Advanced Regenerative Medicine Clinical Research Support Project Group, sharing the status of development and commercialization of advanced therapeutic technologies such as immuno-oncology drugs, vaccines, regenerative medicine, microbiomes, and Alzheimer's disease.

Along with the accelerated digital transformation across all industries brought by COVID-19, the digital transformation of the biohealth industry will also be introduced. The current status of biohealth data utilization for the introduction of precision medicine, the application of artificial intelligence technology in the medical field, and strategies for entering the digital therapeutics (DTx) market will be examined. With the increasing demand for digital healthcare, there is high interest in digital therapeutics, and active research is underway. A session will be held to discuss strategies and directions for digital therapeutics development and business model establishment.

In addition to these changes, a forum will be held to share experts' views on responding to the rapidly changing business environment after COVID-19 and to discuss market response strategies. Although the biohealth industry faced difficulties due to COVID-19, it is evaluated as having adapted to the new situation and used it as an opportunity for self-innovation. This innovation is accelerating changes in the global market and supply chains. At this BIO KOREA, future prospects such as the reorganization of trade order and new trade issues after COVID-19 will be examined, and GVC supply chain management and ESG strategies for overseas expansion of the health industry will be discussed.

Applications and detailed information can be found on the BIO KOREA 2022 website.